Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Genentech has reached an agreement with 23andMe to generate whole-genome sequencing data from 3,000 volunteers with Parkinson’s disease. The two hope to discover new therapeutic targets for treating the nervous system disorder. 23andMe says it will also be able to share the genetic information generated through the project with other researchers. A year ago, FDA ordered 23andMe to stop selling its direct-to-consumer genome test kits without the agency’s approval.
This article has been sent to the following recipient: